Karuna Therapeutics Inc.
KRTX-
Karuna Therapeutics soared 47.4% to $317.22 after Bristol Myers agreed to pay $330 per share, or $14 billion, to acquire the maker of the schizophrenia drug KarXT.
The U.S. Food and Drug Administration has accepted KarXT for a review.
Bristol-Myers declined 1.7% to $50.36.
Dec 22, 2023
|
|
| |
|
| Trading Volume | 1,868,526 |
|
|
329.83 - 161.01 |
| Market Cap Full | $ 12.4B |
Quarterly +
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Q1 | - | 4.2% | -7.6% | -3.2% |
| Q2 | - | - | 19.4% | -0.2% |
| Q3 | - | - | -22% | 77.8% |
| Q4 | - | - | 94.7% | -12.6% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2025 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| -1 | 0.2 | 5.1 | - | - | - | - | - | - | - | - | - |
| 2023 | |||||||||||
| 1.5 | 0 | -8.9 | 9.3 | 14.2 | -4.3 | -7.9 | -6 | -9.9 | -1.5 | 14.8 | 65.5 |
| 2022 | |||||||||||
| -15.2 | -5.5 | 20.8 | -12.1 | -7.1 | 22.2 | 1.8 | 98 | -11.8 | -2.5 | 7.3 | -16.5 |
| 2021 | |||||||||||
| -1.3 | 24.2 | -3.4 | -7.7 | 0.7 | 1.9 | 0.2 | 4.1 | 2.9 | 14.3 | -8.5 | 2.4 |
| 2020 | |||||||||||
| 28 | -13.9 | -10.6 | 15.4 | 13 | 18.8 | -26.6 | -7.4 | 2 | 5 | 22.9 | 1.8 |
EPS
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Q1 | -2.8 | -2 | -1.1 | 0 |
| Q2 | -2.8 | -2.2 | -1.2 | 0 |
| Q3 | -3.2 | -2.4 | -1.7 | 0 |
| Q4 | 0 | -2.2 | -1 | 0 |
| A | -8.71 | -8.7 | -4.9 | -2.6 |